Evaluation of Gynecological and Sexual Sequelae

Summary

Rectal cancer accounts for approximately 40% of colorectal cancers. In France, there are 15,000 new cases per year, and the 5-year survival rate is 55% across all stages. Treatment involves surgical resection of the rectum, often combined with preoperative chemoradiotherapy and sometimes immunotherapy, depending on the tumor's immunohistochemical status. This treatment strategy has improved recurrence-free survival but is associated with long-term functional complications affecting the digestive, urological, gynecological, and sexual systems. Surgery causes anatomical changes and damage to the autonomic nervous system plexuses. Radiotherapy, for its part, causes pelvic inflammation with the development of fibrosis and potential vascular and nerve damage. Various disorders can arise as a result of these anatomical changes, such as erectile dysfunction in men; dyspareunia and vaginal dryness in women; urinary incontinence and impaired sexual quality of life in both sexes.

Eligibility

Inclusion Criteria:

* Women aged 18 to 60 at the time of diagnosis
* Having been treated for rectal cancer between 2020 and 2025
* Cancer in remission
* Having been sexually active before receiving treatment for their rectal cancer
* Having completed the various questionnaires during their treatment

Exclusion Criteria:

* Inability to complete questionnaires (cognitive impairment, language barrier)
* Pregnant women
* Women with active cancer and/or undergoing chemotherapy
* Women with a history of extensive gynecological surgery
* Individuals deprived of their liberty by an administrative or judicial decision, or individuals under legal protection/guardianship or curatorship
* Individuals without social security coverage

Conditions2

Browse More Trials